Non Hodgkin Lymphoma Clinical Trial

AB-101 as Monotherapy and In Combination With Rituximab in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Summary

AB-101 is an off-the shelf, allogeneic cell product made of "natural killer" cells, also called NK cells. White blood cells are part of the immune system and NK cells are a type of white blood cell that are known to kill cancer cells.

This clinical trial is conducted in two phases. The primary objective of Phase 1 is to test the safety of AB-101 given alone or in combination with rituximab. The primary objective of Phase 2 is to determine if AB-101 in combination with rituximab has activity in patients with relapsed/refractory Non-Hodgkin lymphoma of B-cell origin.

Patients will receive eight weekly doses of AB-101 followed by scheduled assessments of overall health and tumor response.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Confirmed diagnosis of indolent or aggressive NHL of B-cell origin
Patient must have progressed or demonstrated intolerance to at least two lines of FDA-approved therapies, one of which must have included anti-CD20 monoclonal antibody therapy. Prior hematopoietic stem cell transplantation or treatment with FDA-approved CAR-T therapy is permitted.
Patient must have disease that allows for response assessment using the Lugano Classification criteria.
For Group 2 patients, confirmed CD20-positive disease

Exclusion Criteria:

Active CNS lymphoma or CNS involvement
Cardiac impairment with symptoms of New York Heart Association Classification of III or IV
Cardiac ejection fraction of < 45% on echocardiogram or MUGA scan at screening assessment
Inadequate pulmonary function
History of a solid organ allograft, or an inflammatory or autoimmune disease likely to be exacerbated by IL-2
Ongoing uncontrolled systemic infections

Study is for people with:

Non Hodgkin Lymphoma

Phase:

Phase 1

Estimated Enrollment:

60

Study ID:

NCT04673617

Recruitment Status:

Recruiting

Sponsor:

Artiva Biotherapeutics, Inc.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 10 Locations for this study

See Locations Near You

University of Alabama
Birmingham Alabama, 35249, United States More Info
Amitkumar Mehta, MD
Contact
205-966-8400
[email protected]
University of California, Irvine
Orange California, 92868, United States More Info
Blake Johnson
Contact
714-456-3476
[email protected]
Lauren C. Pinter-Brown, MD
Principal Investigator
University of California San Diego Moores Cancer Center
San Diego California, 92093, United States More Info
Joseph Maroge
Contact
858-246-0682
[email protected]
Ayad Hamdan, M.D.
Principal Investigator
Blood and Marrow Transplant Group of Georgia at Northside Hospital
Atlanta Georgia, 30342, United States More Info
Stacey Brown
Contact
404-780-7965
[email protected]
Lawrence E Morris, Jr, MD
Principal Investigator
Rush University Medical Center
Chicago Illinois, 60612, United States More Info
Rush Cancer Center Clinical Trials Office
Contact
312-226-2371
[email protected]
Sunita Nathan, MD
Principal Investigator
University of Iowa Hospitals and Clinics
Iowa City Iowa, 52242, United States More Info
Karen Parrott, RN, BSN
Contact
319-353-6347
[email protected]
Umar Farooq, MD
Principal Investigator
Norton Cancer Institute
Louisville Kentucky, 40241, United States More Info
Norton Cancer Institute Hematology
Contact
502-899-3366
[email protected]
Joseph Maly, M.D.
Principal Investigator
Oregon Health Sciences Center
Portland Oregon, 97239, United States More Info
OHSU Clinical Trials Information Line
Contact
503-494-1080
[email protected]
Jennifer Saultz, D.O.
Principal Investigator
Fox Chase Cancer Center
Philadelphia Pennsylvania, 19111, United States More Info
Rashmi Khanal, M.D.
Contact
215-728-4300
[email protected]
Rashmi Khanal, M.D.
Principal Investigator
Texas Oncology - Baylor Charles A. Sammons Cancer Center
Dallas Texas, 75246, United States More Info
Tarah Satterfield, MPH
Contact
214-820-6967
[email protected]
Houston Holmes, MD
Principal Investigator

How clear is this clinincal trial information?

Study is for people with:

Non Hodgkin Lymphoma

Phase:

Phase 1

Estimated Enrollment:

60

Study ID:

NCT04673617

Recruitment Status:

Recruiting

Sponsor:


Artiva Biotherapeutics, Inc.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.